GEP20146004B - Pyridazinone compounds - Google Patents

Pyridazinone compounds

Info

Publication number
GEP20146004B
GEP20146004B GEAP201012363A GEAP2010012363A GEP20146004B GE P20146004 B GEP20146004 B GE P20146004B GE AP201012363 A GEAP201012363 A GE AP201012363A GE AP2010012363 A GEAP2010012363 A GE AP2010012363A GE P20146004 B GEP20146004 B GE P20146004B
Authority
GE
Georgia
Prior art keywords
pyridazinone compounds
pyridazinone
compounds
phosphodiesteraze
schizophrenia
Prior art date
Application number
GEAP201012363A
Other languages
English (en)
Inventor
Makoto Fushimi
Masato Yoshikawa
Jun Kunitomo
John F Quinn
Mitsuyo Kondo
Akira Kawada
Takahiko Taniguchi
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of GEP20146004B publication Critical patent/GEP20146004B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
GEAP201012363A 2009-02-05 2010-02-04 Pyridazinone compounds GEP20146004B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20220709P 2009-02-05 2009-02-05
US21392709P 2009-07-30 2009-07-30

Publications (1)

Publication Number Publication Date
GEP20146004B true GEP20146004B (en) 2014-01-10

Family

ID=42398214

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP201012363A GEP20146004B (en) 2009-02-05 2010-02-04 Pyridazinone compounds

Country Status (37)

Country Link
US (7) US8916566B2 (enExample)
EP (2) EP3006031A1 (enExample)
JP (1) JP5659166B2 (enExample)
KR (1) KR101730665B1 (enExample)
CN (1) CN102365020B (enExample)
AR (1) AR075238A1 (enExample)
AU (1) AU2010211050B2 (enExample)
BR (1) BRPI1008498B8 (enExample)
CA (1) CA2751565C (enExample)
CO (1) CO6410258A2 (enExample)
CR (1) CR20110440A (enExample)
DK (1) DK2393360T3 (enExample)
DO (1) DOP2011000254A (enExample)
EA (1) EA020690B1 (enExample)
EC (1) ECSP11011305A (enExample)
ES (1) ES2561181T3 (enExample)
GE (1) GEP20146004B (enExample)
HR (1) HRP20160065T1 (enExample)
HU (1) HUE027478T2 (enExample)
IL (1) IL214137A (enExample)
JO (1) JO3114B1 (enExample)
MA (1) MA33072B1 (enExample)
ME (1) ME02337B (enExample)
MX (1) MX2011008305A (enExample)
MY (1) MY170610A (enExample)
NZ (1) NZ594851A (enExample)
PE (1) PE20110991A1 (enExample)
PL (1) PL2393360T3 (enExample)
RS (1) RS54504B1 (enExample)
SG (1) SG173175A1 (enExample)
SI (1) SI2393360T1 (enExample)
SM (1) SMT201600008B (enExample)
TN (1) TN2011000362A1 (enExample)
TW (1) TWI457333B (enExample)
UY (1) UY32417A (enExample)
WO (1) WO2010090737A1 (enExample)
ZA (1) ZA201106074B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009054791A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mglur5
JP5627574B2 (ja) * 2008-06-03 2014-11-19 インターミューン, インコーポレイテッド 炎症性および線維性疾患を治療するための化合物および方法
ME02337B (me) * 2009-02-05 2016-06-20 Takeda Pharmaceuticals Co Jedinjenja piridazinona
WO2011163355A1 (en) 2010-06-24 2011-12-29 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors
WO2012009194A1 (en) * 2010-07-12 2012-01-19 Merck Sharp & Dohme Corp. Tyrosine kinase inhibitors
EP2601192B1 (en) 2010-08-04 2017-03-01 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
US8883788B2 (en) 2010-08-04 2014-11-11 Takeda Pharmaceutical Company Limited Fused heterocyclic ring compound
WO2012018059A1 (ja) 2010-08-04 2012-02-09 武田薬品工業株式会社 複素環化合物
EP2604597B1 (en) * 2010-08-10 2017-01-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof inhibitor of phosphodiesterase 10a
JP2013234123A (ja) * 2010-09-03 2013-11-21 Taisho Pharmaceutical Co Ltd 3−ピラゾリル−2−ピリドン誘導体
MX2013009575A (es) 2011-02-18 2014-10-14 Exonhit Therapeutics Sa Derivados de 6, 7-dialcoxi-3-isoquinolinol sustituidos como inhibidores de fosfodiesterasa 10 (pdei0a).
EP2687529B1 (en) 2011-03-16 2016-07-13 Takeda Pharmaceutical Company Limited Condensed heterocyclic compound
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
JP6153513B2 (ja) * 2011-08-22 2017-06-28 武田薬品工業株式会社 哺乳類中のホスホジエステラーゼ(pde10a)を定量的に画像化する放射性トレーサとしての放射標識された化合物及びその用途
US9212147B2 (en) 2011-11-15 2015-12-15 Takeda Pharmaceutical Company Limited Dihydroxy aromatic heterocyclic compound
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
JP6364420B2 (ja) 2013-02-21 2018-07-25 武田薬品工業株式会社 ピリダジノン化合物の製造方法
WO2014142322A1 (ja) 2013-03-15 2014-09-18 第一三共株式会社 ベンゾチオフェン誘導体
WO2015006689A1 (en) 2013-07-12 2015-01-15 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression
HK1225382A1 (zh) * 2013-09-12 2017-09-08 Alios Biopharma, Inc. 噠嗪酮化合物及其用途
PE20160661A1 (es) 2013-09-12 2016-08-05 Alios Biopharma Inc Compuesto de azapiridona y sus usos de los mismos
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
ES2544869B2 (es) * 2014-03-04 2016-01-18 Universidade De Vigo Derivados de piridazin-3(2H)-ona inhibidores selectivos de la isoforma B de la monoaminooxidasa
US10231929B2 (en) 2014-03-18 2019-03-19 Takeda Pharmaceutical Company Limited Solid dispersion
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
US10208045B2 (en) 2015-03-11 2019-02-19 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
WO2016191935A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
CN107428721B (zh) 2015-12-22 2020-07-28 江苏恒瑞医药股份有限公司 苯并哌啶类衍生物、其制备方法及其在医药上的应用
US10736894B2 (en) 2018-02-15 2020-08-11 Ovid Therapeutics Inc. Methods of treating developmental syndromes with PDE10A inhibitors
CN108498868B (zh) * 2018-04-03 2020-09-15 北京大学口腔医学院 具有细胞外基质电学拓扑特征的带电复合膜及其制备方法
CN110407806B (zh) * 2018-04-28 2021-08-17 深圳微芯生物科技股份有限公司 甲酰胺类化合物、其制备方法及其应用
WO2019241787A1 (en) * 2018-06-15 2019-12-19 The Regents Of The University Of Colorado A Body Corporate Novel cyclic gmp-amp synthase (cgas) inhibitors and their method of use
JP2022501335A (ja) * 2018-09-28 2022-01-06 武田薬品工業株式会社 自閉症スペクトラム障害を治療または予防するためのバリポデクト(Balipodect)
MX2019008440A (es) 2019-07-15 2021-01-18 Dva Farma Mexicana S A De C V Composiciones de recubrimientos en pelicula para tabletas con brillantez incrementada, procedimiento de preparacion y aplicacion.
EP3805206A1 (en) * 2019-10-08 2021-04-14 Novaled GmbH Compound and an organic semiconducting layer, an organic electronic device, a display device and a lighting device comprising the same
GB202002926D0 (en) 2020-02-28 2020-04-15 Benevolentai Tech Limited Compositions and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0011693A1 (de) 1978-10-03 1980-06-11 Ciba-Geigy Ag Neue N-(trifluormethansulfonylaminophenyl)-substituierte N-Heterocyclen, ihre Herstellung, sie enthaltende Mittel und ihre Verwendung zur Beeinflussung des Pflanzenwachstums
FR2648135B1 (fr) * 1989-06-07 1991-09-27 Pf Medicament Derives de phenyl-1-dihydro-1,4 amino-3 oxo-4 pyridazines, leur preparation et leur application en therapeutique
GB9506382D0 (en) 1995-03-29 1995-05-17 Boots Co Plc Pharmaceutical compositions
CA2340230C (en) 1998-08-14 2008-03-11 Nihon Nohyaku Co., Ltd. Pyridazinone derivatives having cell adhesion inhibiting activity
US20070060606A1 (en) 1999-10-07 2007-03-15 Robertson Harold A Compounds and methods for modulating phosphodiesterase 10A
GB0013383D0 (en) 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
ATE346064T1 (de) 2000-09-15 2006-12-15 Vertex Pharma Pyrazolverbindungen als protein-kinasehemmer
US7005432B2 (en) 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
CA2568929A1 (en) 2004-06-07 2005-12-22 Pfizer Products Inc. Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions
EP1769092A4 (en) 2004-06-29 2008-08-06 Europ Nickel Plc IMPROVED LIXIVIATION OF BASE METALS
AU2005323794B2 (en) 2005-01-07 2012-07-19 Pfizer Products Inc. Heteroaromatic quinoline compounds and their use as PDE10 inhibitors
WO2006095666A1 (ja) * 2005-03-07 2006-09-14 Kyorin Pharmaceutical Co., Ltd. ピラゾロピリジン-4-イルピリダジノン誘導体とその付加塩及びそれらを有効成分とするpde阻害剤
CA2654394A1 (en) 2006-06-26 2008-01-03 Pfizer Products Inc. Tricyclic heteroaryl compounds as pde10 inhibitors
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
US20080090834A1 (en) 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
JP2011507910A (ja) 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
WO2010000020A1 (en) 2008-06-30 2010-01-07 Cathrx Ltd A catheter
TW201030001A (en) 2008-11-14 2010-08-16 Amgen Inc Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
TWI396689B (zh) 2008-11-14 2013-05-21 Amgen Inc 作為磷酸二酯酶10抑制劑之吡衍生物
EP2373641B1 (en) * 2008-12-04 2012-12-19 F. Hoffmann-La Roche AG Pyridazinone derivatives
ME02337B (me) 2009-02-05 2016-06-20 Takeda Pharmaceuticals Co Jedinjenja piridazinona
US9187455B2 (en) 2009-02-23 2015-11-17 Hoffmann-La Roche Inc. Substituted pyridazines as PDE10A inhibitors
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
US8883788B2 (en) * 2010-08-04 2014-11-11 Takeda Pharmaceutical Company Limited Fused heterocyclic ring compound
EP2604597B1 (en) * 2010-08-10 2017-01-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof inhibitor of phosphodiesterase 10a

Also Published As

Publication number Publication date
ME02337B (me) 2016-06-20
JO3114B1 (ar) 2017-09-20
US8354411B2 (en) 2013-01-15
CN102365020A (zh) 2012-02-29
PL2393360T3 (pl) 2016-04-29
US8435995B2 (en) 2013-05-07
US8916566B2 (en) 2014-12-23
US8513251B2 (en) 2013-08-20
DK2393360T3 (en) 2016-02-01
CO6410258A2 (es) 2012-03-30
EP2393360A4 (en) 2012-08-15
IL214137A0 (en) 2011-08-31
HUE027478T2 (en) 2016-09-28
AR075238A1 (es) 2011-03-16
PE20110991A1 (es) 2012-02-06
EP2393360A1 (en) 2011-12-14
US20100197651A1 (en) 2010-08-05
IL214137A (en) 2015-07-30
US20120277204A1 (en) 2012-11-01
MY170610A (en) 2019-08-20
US20120028951A1 (en) 2012-02-02
TN2011000362A1 (en) 2013-03-27
US20170114044A1 (en) 2017-04-27
BRPI1008498B8 (pt) 2021-05-25
TW201036958A (en) 2010-10-16
WO2010090737A1 (en) 2010-08-12
CN102365020B (zh) 2014-07-30
DOP2011000254A (es) 2011-09-30
UY32417A (es) 2010-08-31
US8778944B2 (en) 2014-07-15
EP2393360B1 (en) 2015-11-04
HRP20160065T1 (hr) 2016-02-12
MX2011008305A (es) 2012-08-15
CA2751565C (en) 2017-05-16
US20150099757A1 (en) 2015-04-09
CR20110440A (es) 2012-02-13
JP5659166B2 (ja) 2015-01-28
EA201171004A1 (ru) 2012-03-30
BRPI1008498B1 (pt) 2020-02-11
AU2010211050B2 (en) 2016-05-12
BRPI1008498A2 (pt) 2015-08-25
ES2561181T3 (es) 2016-02-24
SG173175A1 (en) 2011-09-29
US20120277430A1 (en) 2012-11-01
TWI457333B (zh) 2014-10-21
RS54504B1 (sr) 2016-06-30
AU2010211050A1 (en) 2011-09-08
MA33072B1 (fr) 2012-02-01
ZA201106074B (en) 2012-10-31
KR20110120931A (ko) 2011-11-04
JP2012516890A (ja) 2012-07-26
EA020690B1 (ru) 2015-01-30
EP3006031A1 (en) 2016-04-13
KR101730665B1 (ko) 2017-04-26
CA2751565A1 (en) 2010-08-12
NZ594851A (en) 2013-10-25
US9550756B2 (en) 2017-01-24
ECSP11011305A (es) 2011-11-30
SMT201600008B (it) 2016-02-25
US20120277431A1 (en) 2012-11-01
AU2010211050A2 (en) 2011-10-06
HK1164642A1 (zh) 2012-09-28
SI2393360T1 (sl) 2016-02-29

Similar Documents

Publication Publication Date Title
GEP20146004B (en) Pyridazinone compounds
MX2010009736A (es) Compuesto heterociclico.
GEP20156372B (en) Pyridazinone compounds and their use as daao inhibitors
UA104885C2 (uk) Ізотіазолілоксифеніламідини та їх застосування як фунгіцидів
PH12012500674A1 (en) Heterocyclic compounds useful as pdk1 inhibitors
MY162933A (en) Chemical compounds
GEP201706691B (en) Substituted phthalazin-1 (2h)-one derivatives as selecti- ve inhibitors of poly (adp-ribose) polymerase-1
GEP20146102B (en) Compounds and compositions as protein kinase inhibitors
MX2011006631A (es) Inhibidores de proteasa ns3 del virus hcv.
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
GEP20156329B (en) CHEMICAL MODIFICATIONS OF miRNA INHIBITORS AND MIMETICS
MX2010009765A (es) Moleculas pequeñas que contienen boro como agentes anti-inflamatorios.
IN2012DN00869A (enExample)
UA111161C2 (uk) Похідна фталазинонкетону, спосіб її одержання та її фармацевтичне застосування
GEP20146125B (en) Aminopyrimidines as syk inhibitors
MX2012000709A (es) Inhibidores de pirrolopiridina de cinasas.
SG178952A1 (en) Chemical compounds
GB0920703D0 (en) Compositions containing satiogens and methods of use
PH12012501631A1 (en) Pyrimidine derivatives and their use in the treatment of respiratory diseases such as copd
TN2012000578A1 (en) Tetrahydro-pyrido-pyrimidine derivatives
GEP20146131B (en) Carbazole compounds and therapeutic uses thereof
MX2013005994A (es) Monobactamas.
PH12012501630A1 (en) Pyrimidine derivatives and their use in the treatment of respiratory diseases such as copd
MX2012004780A (es) Inhibidores de akt.
UA105000C2 (uk) ГЕТЕРОЦИКЛІЧНІ ІНГІБІТОРИ СТЕАРОЇЛ-СоА-ДЕСАТУРАЗИ